BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Price & Overview
NASDAQ:BMRN • US09061G1013
The current stock price of BMRN is 60.89 USD. Today BMRN is up by 0.02%. In the past month the price increased by 5.33%. In the past year, price decreased by -12.31%.
BMRN Key Statistics
- Market Cap
- 11.71B
- P/E
- 34.21
- Fwd P/E
- 13.02
- EPS (TTM)
- 1.78
- Dividend Yield
- N/A
BMRN Stock Performance
BMRN Stock Chart
BMRN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BMRN. When comparing the yearly performance of all stocks, BMRN turns out to be only a medium performer in the overall market: it outperformed 42.99% of all stocks.
BMRN Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to BMRN. BMRN scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
BMRN Earnings
On February 23, 2026 BMRN reported an EPS of -0.24 and a revenue of 874.57M. The company missed EPS expectations (-137.68% surprise) and beat revenue expectations (3.57% surprise).
BMRN Forecast & Estimates
32 analysts have analysed BMRN and the average price target is 92.49 USD. This implies a price increase of 51.9% is expected in the next year compared to the current price of 60.89.
For the next year, analysts expect an EPS growth of 162.78% and a revenue growth 12.65% for BMRN
BMRN Groups
Sector & Classification
BMRN Financial Highlights
Over the last trailing twelve months BMRN reported a non-GAAP Earnings per Share(EPS) of 1.78. The EPS decreased by -19.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.83% | ||
| ROA | 4.59% | ||
| ROE | 5.73% | ||
| Debt/Equity | 0.1 |
BMRN Ownership
BMRN Latest News, Press Relases and Analysis
BMRN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.3 | 401.392B | ||
| AMGN | AMGEN INC | 16.45 | 202.383B | ||
| GILD | GILEAD SCIENCES INC | 16.81 | 184.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.75 | 126.804B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.51 | 81.619B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.21 | 42.754B | ||
| INSM | INSMED INC | N/A | 31.007B | ||
| NTRA | NATERA INC | N/A | 28.197B | ||
| BIIB | BIOGEN INC | 11.72 | 27.651B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.94 | 23.485B | ||
| MRNA | MODERNA INC | N/A | 21.714B | ||
| EXAS | EXACT SCIENCES CORP | 340.08 | 19.732B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.591B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BMRN
Company Profile
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,221 full-time employees. The firm has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
Company Info
IPO: 1999-07-23
BIOMARIN PHARMACEUTICAL INC
770 Lindaro Street
San Rafael California CALIFORNIA 94901 US
CEO: Jean-Jacques Bienaime
Employees: 3221
Phone: 14155066700
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you describe the business of BIOMARIN PHARMACEUTICAL INC?
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,221 full-time employees. The firm has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
What is the current price of BMRN stock?
The current stock price of BMRN is 60.89 USD. The price increased by 0.02% in the last trading session.
What is the dividend status of BIOMARIN PHARMACEUTICAL INC?
BMRN does not pay a dividend.
What is the ChartMill technical and fundamental rating of BMRN stock?
BMRN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the Price/Earnings (PE) ratio of BIOMARIN PHARMACEUTICAL INC (BMRN)?
The PE ratio for BIOMARIN PHARMACEUTICAL INC (BMRN) is 34.21. This is based on the reported non-GAAP earnings per share of 1.78 and the current share price of 60.89 USD.
Is BIOMARIN PHARMACEUTICAL INC (BMRN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BMRN.
What is BIOMARIN PHARMACEUTICAL INC worth?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a market capitalization of 11.71B USD. This makes BMRN a Large Cap stock.